Long-term outcome data in @entity788 are predominantly based on surgical series, as resection is currently considered essential for long-term survival. In contrast, five-year survival in non-resected @entity1 has rarely been reported. In this report, we examined the incidence and natural history of >=  5-year survivors with non-resected @entity788 . All @entity1 with @entity788 who received oncologic therapy alone without surgery at our institution between 1995 and 2009 were identified. Non-resected >=  5-year survivors represented 2% (11/544) of all non-resected @entity1 undergoing treatment for @entity788 , and 11% (11/98) of >=  5-year survivors. Nine @entity1 had localized @entity5 and 2 metastatic disease at initial diagnosis. Disease progression occurred in 6 @entity1 , and the local @entity5 bed was the most common site of progression. Six @entity1 suffered from significant morbidities including recurrent @entity255 , second @entity5 , @entity29 . A rare subset of @entity1 with @entity788 achieve long-term survival without resection. Despite prolonged survival, morbidities unrelated to the primary @entity5 were frequently encountered and a close follow-up is warranted in these @entity1 . Factors such as @entity5 biology and host immunity may play a key role in disease progression and survival.

Rare long-term survivors of XXXX without curative resection.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer', 'pancreatic adenocarcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'malignancy'] @entity29 :: ('MESH:D015212', 'Disease') :: ['malnutrition and bowel perforation'] @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic adenocarcinoma']
